Published in FDA Law Weekly, September 15th, 2005
Research and development (R&D) expenses in the third fiscal quarter of 2005 were $6.5 million, compared to $5.1 million in the same period a year ago. R&D program highlights for the third quarter were:
1) Submitting the final reviewable unit of our new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Neurodex in the treatment of pseudobulbar affect, including the payment of a $672,000 filing fee;
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.